^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:Cotellic (cobimetinib) (MEK1 inhibitor) +
    UNC2025 (FLT3 inhibitor, MERTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

    Excerpt:
    In patient-derived melanoma xenograft models, treatment with UNC2025 blocked or significantly reduced tumor growth...Similarly, in NRAS-mutated cell lines, addition of UNC2025 to cobimetinib therapy increased cell death and decreased colony-forming potential.
    DOI:
    10.1158/1535-7163.MCT-18-0456